Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine for Carbon-11 Butanol Clearance from vCSF in Healthy Volunteers
NCT04032691Phase 1Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2019
- Primary completion
- May 2021
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Clonidine Lauriad, sponsored by Weill Cornell Medicine. Primary endpoint: Number of Adverse Events at 1 week. Planned start Aug 2019; status: withdrawn.
02
Drugs
Clonidine Lauriad
Beyond the preview
Go deeper on NCT04032691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032691.